Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Subjects with locally invasive or metastatic, epithelial ovarian, fallopian tube, or primary peritoneal cancer
Subjects must provide samples of tumor tissue
Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not be if
Subjects with low-grade ovarian, fallopian tube, or Primary peritoneal cancer
Women who are pregnant or breast feeding
Subjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocol
Clareo Health | Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
